Today: 29 June 2026
Browse Category

NASDAQ:CYTK 30 August 2025 - 1 January 2026

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics, Incorporated surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday high near $70.86—a move that pushed the biotech to fresh 52-week highs and re-focused Wall Street on the commercial potential of its newly approved heart drug, Myqorzo. Investing.com The immediate catalyst is straightforward: the U.S. Food and Drug Administration approved Myqorzo on December 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy. But the market reaction on December 22 suggests investors are pricing in something bigger than “approval happened.” They’re reacting to the details—the label, the monitoring requirements, and the belief among several analysts that Myqorzo may be easier to use than the incumbent drug in its class. Reuters+1
22 December 2025
·
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease acquisition, a closely watched FDA approval in cardiology, IPO paperwork from both biotech and medtech, and a sweeping wave of U.S. drug-pricing headlines that could reshape sentiment into 2026. Investopedia+4Reuters+4Reuters+4 The setup matters because next week’s market structure will be unusual: U.S. stock markets are scheduled to close early on Wednesday, December 24 and remain closed on Thursday, December 25 for Christmas Day. That kind of thin liquidity can magnify single-stock moves—especially in biotech, where headlines often arrive without warning. New York Stock Exchange+2Nasdaq+2
21 December 2025
·····
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org. Another study this week revealed a promising cardiovascular benefit from vaccination. An analysis presented at the European Society of Cardiology Congress found that getting the shingles vaccine is associated with significantly lower rates of heart attacks and strokes reuters.com. Pooled data from nine studies
30 August 2025
····

Stock Market Today

  • Kimco Realty (KIM.PRL) Sets Quarterly Preferred Dividend; Ex-Date July 1
    June 29, 2026, 3:11 PM EDT. Kimco Realty Corp's Class L Preferred Stock (KIM.PRL) goes ex-dividend July 1, 2026, with $0.3203 per share due July 15. At Friday's close of $19.33, the annualized yield is about 6.63%. On the ex-date, shares are set to drop by about 1.66%. That payout is lower than the 8.12% average for preferreds in Real Estate. Monday, KIM.PRL eked out a 0.1% gain, while Kimco common (KIM) was unchanged. Kimco makes up 3.28% of the Invesco S&P 500 Equal Weight Real Estate ETF (RSPR). Preferred stocks such as KIM.PRL appeal to investors looking for steady real estate income.
Go toTop